Recent advances in small molecule inhibitors of VEGFR and EGFR signaling pathways

Haizhen Zhong, J. Phillip Bowen

Research output: Contribution to journalReview article

39 Scopus citations

Abstract

Aberrant angiogenesis has been observed in many solid tumors. The formation and metastases of tumors such as non-small cell lung cancer (NSCLC) and renal cell carcinoma (RCC) are very complex, often regulated by proangiogenic factors such as the vascular endothelial growth factor (VEGF) and other tyrosine kinases. The VEGFR, EGFR and mTOR pathways have played critical roles in controlling cell proliferation and angiogenesis. This paper reviews the mechanism and binding modes of recently approved tyrosine kinase inhibitors (TKIs), such as gefitinib, erlotinib, nilotinib, dasatinib, sunitinib, sorafenib, pazopanib, lapatinib, afinitor, and temsirolimus. We also cover the progresses of the recent development of tyrosine kinase inhibitors that are currently in the clinical trials at the phases I, II, and III, targeting the VEGFR, EGFR and/or mTOR pathways. Combination therapy intended to overcome drug resistance is also discussed. Recent TKI design based on the activation loop and the "DFG" conformation, is also discussed.

Original languageEnglish (US)
Pages (from-to)1571-1590
Number of pages20
JournalCurrent Topics in Medicinal Chemistry
Volume11
Issue number12
DOIs
StatePublished - Jun 1 2011

    Fingerprint

Keywords

  • AEE788
  • And ponatinib
  • Axitinib
  • BIBF1120
  • Brivanib
  • Cediranib
  • Dovitinib
  • E7080
  • Linifanib
  • Motesanib
  • Regorafenib
  • SU5416
  • Tandutinib
  • Telatinib
  • Tivozanib
  • Vandetanib
  • Vatalanib
  • XL880

ASJC Scopus subject areas

  • Drug Discovery

Cite this